Search | Clinical Trials Finder

Conditions: COVID-19
Interventions: Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more

Conditions: COVID-19
Interventions: VIR-7831, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 74
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more

Conditions: Cough, Sore Throat, Nasal Congestion, Headache, Fever, Seasonal Influenza
Interventions: Peramivir+SOC, Placebo+SOC; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 60
States / cities: La Mesa, California • Long Beach, California • Modesto, California + 49 more

Conditions: Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions: Tocilizumab (TCZ), Placebo, Standard of Care; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more

Conditions: Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions: SNDX-6352, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • The Bronx, New York

Conditions: Non-small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more

Conditions: Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Interventions: Niraparib, Dostarlimab (TSR-042), Standard of care, Dostarlimab-Placebo, Niraparib-Placebo; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 65
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 55 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 337
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more

Conditions: COVID-19
Interventions: PF-07304814, Placebo, Remdesivir; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Chula Vista, California • Los Angeles, California • Mather, California + 23 more

Conditions: Generalized Pustular Psoriasis
Interventions: Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab, Standard of Care (SOC), Imsidolimab 750 mg IV/200 mg SC; Drug · Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more

Conditions: COVID-19
Interventions: BRII-196, BRII-198, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 76
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more

Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions: Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide; Drug
Lead sponsor: Leaf Vertical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions: ornithine phenylacetate, placebo intravenous infusion; Drug
Lead sponsor: Ocera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo; Drug · Biological · Other
Lead sponsor: Donald T. Weed, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Covid19
Interventions: LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 98
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more

Conditions: COPD
Interventions: Zofin, Placebo; Drug · Other
Lead sponsor: ZEO ScientifiX, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001, Placebo (NNC6019-0001); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 63
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 49 more

Conditions: Multiple Myeloma
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington

Conditions: Bacteremia
Interventions: DSTA4637S, Placebo, SOC; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more

Conditions: Malignant Digestive System Neoplasm
Interventions: Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration; Procedure · Drug · Device + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID-19
Interventions: MP0420, Placebo, Remdesivir; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 73
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 52 more

Conditions: COVID-19
Interventions: LY3819253, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 42
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more

Conditions: Endometrial Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more

Search by objective public record fields.

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

ACTIV-3: Therapeutics for Inpatients With COVID-19

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)